Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia
| Autor: | Sunita Ghosh, Joseph Brandwein, Irwindeep Sandhu, Artur J. Szkotak, Lalit Saini |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Multivariate analysis Adolescent Karyotype Gastroenterology 03 medical and health sciences Young Adult 0302 clinical medicine Bone Marrow Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Young adult Aged Chromosome Aberrations business.industry Biopsy Needle Remission Induction Cytogenetics Induction chemotherapy Myeloid leukemia Hematology Middle Aged Leukemia Myeloid Acute medicine.anatomical_structure Treatment Outcome Oncology Trephine 030220 oncology & carcinogenesis Female Bone marrow business 030215 immunology |
| Zdroj: | Leukemialymphoma. 59(1) |
| ISSN: | 1029-2403 |
| Popis: | We evaluated the impact of bone marrow sample characteristics on the detection of persistent cytogenetic abnormalities (PCA) following induction chemotherapy for acute myeloid leukemia (AML). PCA's were identified in 20.4% of patients and were more common with complete remission without count recovery (CRi) vs. those with count recovery (CR, 45.8 vs. 13.5%, p = .001), with >2% blasts vs. ≤2% blasts (42 vs. 12%, p = .001) and with hypocellular trephine biopsies relative to those with normo/hypercellular biopsies (42.1 vs. 17.3%, p = .03), although in a multivariate analysis only CRi and blast count >2% were independently associated with a PCA. PCA's were not observed in patients with favorable risk karyotype. Amongst patients with intermediate and unfavorable risk karyotypes PCA were not associated with differences in overall or, amongst non-transplanted patients, relapse free survival. Thus, although PCAs are common post-induction it is unclear whether they provide any independent prognostic information beyond the diagnostic karyotype. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|